News | Cath Lab | November 09, 2016

Coronary Stent Study Evaluates Adverse Events in Women, Minorities

Results from the PLATINUM DIVERSITY Study presented at TCT 2016 

 PLATINUM DIVERSITY, stents in minorities and women

November 9, 2016 — A dedicated stent study conducted exclusively in women and minority patients evaluated clinical outcomes within the era of contemporary percutaneous coronary interventions (PCI), comparing these results to a parallel cohort of white male patients. Although there were no significant differences in stent-related outcomes, both groups had higher rates of death and myocardial infarction (MI) in the first year following the procedure. 

Findings from the PLATINUM DIVERSITY trial were reported at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. 

Although people of color are expected to represent more than half (52%) of the U.S. population by 2050, current “all-comers” clinical trial design do not result in a random selection of U.S. patients. As a result, women and minorities have been significantly underrepresented in most cardiology trials. This multicenter, single-arm, prospective “enriched” cohort study enrolled 1,501 women and minorities at 52 sites in the United States. The trial used the Boston Scientific Promus Premier everolimus-eluting stent. Patient information was pooled with data from the PROMUS ELEMENT PAS Study (PE Plus PAS, n=2,687) and each group was compared with white men enrolled in the PE Plus PAS (n=1,635).

“This study draws important attention to differences in clinical outcomes after stent implantation in women and minorities,” said Wayne B. Batchelor, MD, MHS, co-principal investigator from Southern Medical Group in Tallahassee, FL. “The adjusted risk of MI and death/MI was higher in minorities versus white men. In addition, the adjusted risk of death/MI was higher in women than white men with a trend towards higher rates of MI. The similar rates of TVR and stent thrombosis among all three groups suggest that ‘stent failure’ is unlikely to account for the observed differences in outcome. Further study into the cause of these observed gradients of risk is necessary to gain insight into the potential impact on clinical practice.”

The combined primary endpoint of death, Ml and target vessel revascularization (TVR) at 12 months was 7.6% for white men compared with 9.6% (P=0.08) for minorities and 8.6% (P=0.33) for women. Data from the individual components of the primary endpoint found that minorities had the highest rate of death and MI whereas white men had the highest rate of TVR:

•    Death was 3.7% in minorities (P=0.03) and 3.4% in women (P=0.04) compared with white men (2.2%).
•    MI was 3.1% (P=0.0002) in minorities and 1.9% in women (P=0.06) compared with white men (1.1%).
•    TVR was 5.4% (P=0.97) in minorities and 4.6% in women (P=0.27) compared with white men (5.5%).

“The PLATINUM DIVERSITY trial represents an important example of how we can enrich our understanding of outcomes in the underrepresented population. This is the first trial exclusively enrolling women and minorities undergoing PCI and allows for further evaluation of patients who are usually not represented in clinical studies,” said Roxana Mehran, M.D., professor of medicine, Icahn School of Medicine at Mount Sinai and Co-PI of the PLATINUM DIVERSITY study.

The PLATINUM DIVERSITY trial was funded by Boston Scientific. Batchelor reported grant/research support from Boston Scientific and consulting fees/honoraria from Abbott, Boston Scientific and Medtronic.

Read the article “Boston Scientific Initiates Study Of Promus Premier Coronary Stent in Underserved Patient Populations."

 
For more information: www.crf.org

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021